Month: April 2024

AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative psychiatry and neurology pipeline at the American Academy of Neurology (AAN) 2024 annual meeting, being held April 13-18, 2024, in Denver, Colorado. The presentations include an oral presentation during the Clinical Trials Plenary Session of data from the ACCORD Phase 3 trial of AXS-05 in Alzheimer’s disease agitation (ADA). Presentations...

TORONTO, April 15, 2024 (GLOBE NEWSWIRE) — Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (FSE: B4IF) (the “Company” or “Goliath”) is pleased to report it has fast tracked its 49% ownership interest in the Golddigger Property (the “Property”), located in the “Golden Triangle”, British Columbia based on positive results to date. The Company has made all payments required to the vendor under its option agreement dated April 18, 2017 (the “Option Agreement”). It has exceeded the minimum exploration expenditures of $14,000,000 to ultimately earn a 100% interest in the Property. Goliath will earn the remaining 51% interest in the Property by issuing a National Instrument 43-101 (“NI 43-101”) resource estimate showing a minimum of 2,000,000 AuEq ounces on or before June 1, 2027. Key points to the amendment provide for Goliath’s...

ANN ARBOR, Mich., April 15, 2024 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company” or “Kraig Labs”), announces today that the spring production trials for the new BAM-1 hybrid have begun and are well on track to meet the Company’s expectations and timeline. The Company successfully launched the production trials of BAM-1, its newest and most robust recombinant spider silk production silkworm hybrid, on time and in line with its production roadmap. The Company’s CEO remains in Asia to directly oversee the production trial of the BAM-1 parental strains and monitor their performance. Following health screenings and daily monitoring of the colony, the Company can now report that this is currently the strongest and healthiest batch of silkworms it has ever produced...

Tozier is strategic advisor to the CEO, and former executive vice president and chief financial officer of Albemarle Corporation WILMINGTON, Del., April 15, 2024 (GLOBE NEWSWIRE) — Effective today, Ashland Inc. (NYSE: ASH) has announced the appointment of Scott A. Tozier, strategic advisor to the CEO and former executive vice president and chief financial officer of Albemarle Corporation to its Board of Directors. Tozier will serve on the Board’s Audit Committee and Environmental, Health, Safety and Quality Committee, each also effective April 15, 2024. Prior to Albemarle, Tozier held several leadership positions at Honeywell International, Inc. and served on the Board of Directors for Garrett Motion, Inc. Tozier is an experienced global executive with strong industry leadership in financial management, mergers and acquisitions,...

At the end of March 2024, the net asset value (NAV) of UAB “Atsinaujinančios energetikos investicijos” including success fee-accrual decreased to EUR 114,055,438 compared to the previously determined NAV at the end of December 2023 which amounted to EUR 115,325,513. The share price including success fee-accrual decreased to EUR 1.9445 compared to the previously determined share price which at the end of December 2023, amounted to EUR 1.9661. The pro-forma internal rate of return (IRR) since inception including success fee-accrual decreased to 9.48% compared to the previously announced IRR of December 2023, which amounted to 11.15% At the end of March 2024, the NAV excluding success fee accrual decreased to EUR 114,996,122 compared to the previously determined NAV at the end of December 2023, which amounted to EUR 117,108,358. The share...